Retrospective Cohort Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
Shinya Yamada, Takumi Kawakami, Yoshikazu Nakatsugawa, Takahiro Suzuki, Hideki Fujii, Naoya Tomatsuri, Hideki Nakamura, Hideki Sato, Yusuke Okuyama, Hiroyuki Kimura, Norimasa Yoshida
Shinya Yamada, Takumi Kawakami, Yoshikazu Nakatsugawa, Takahiro Suzuki, Hideki Fujii, Naoya Tomatsuri, Hideki Nakamura, Hideki Sato, Yusuke Okuyama, Hiroyuki Kimura, Norimasa Yoshida, Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan
Author contributions: Yamada S and Yoshida N contributed to study conception and design; they also contributed to writing, editing and final approval of article; Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y and Kimura H performed the research.
Institutional review board statement: The study protocol was approved by the Ethics Committee of Japanese Red Cross Kyoto Daiichi Hospital.
Informed consent statement: All study participants, or their legal guardian, provided informed verbal consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Shinya Yamada, Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Hon-machi 15-749, Kyoto 605-0981, Japan. syo335@koto.kpu-m.ac.jp
Telephone: +81-75-5611121 Fax: +81-75-5616308
Received: June 15, 2016
Peer-review started: June 17, 2016
First decision: July 20, 2016
Revised: July 28, 2016
Accepted: August 27, 2016
Article in press: August 29, 2016
Published online: November 6, 2016
Processing time: 137 Days and 21.3 Hours
Core Tip

Core tip: Use of vonoprazan, a potassium ion-competitive acid blocker, is expected to achieve a higher eradication rate than conventional triple therapy. The success rates of the 2 regimens (use of proton pump inhibitor vs vonoprazan) were compared. The success rate of primary Helicobacter pylori (H. pylori) eradication was significantly higher in the vonoprazan group. When stratified by the underlying disease, a significant increase of the H. pylori eradication rate was observed in patients with chronic gastritis. Vonoprazan is very useful for primary eradication of H. pylori, and may become a first-line acid secretion inhibitor instead of proton pump inhibitors.